Louis A. Chedid

Louis A. Chedid's AcademicInfluence.com Rankings

Louis A. Chedid

Philosophy

#6562

World Rank

#9618

Historical Rank

Logic

#3711

World Rank

#4909

Historical Rank

philosophy Degrees

Louis A. Chedid

Biology

#8904

World Rank

#12042

Historical Rank

Neuroscience

#1272

World Rank

#1317

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Louis A. Chedid's Degrees

Doctorate Medicine Stanford University

Why Is Louis A. Chedid Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Louis A. Chedid's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sleep-promoting effects of endogenous pyrogen (interleukin-1). (1984) (447)
Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. (1985) (280)
Current status of immunological adjuvants. (1986) (271)
Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. (1977) (228)
Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. (1978) (203)
Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. (1979) (203)
Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. (1979) (185)
A proposed mechanism for natural immunity to enterobacterial pathogens. (1968) (184)
Modulation of the immune response by a synthetic adjuvant and analogs. (1976) (180)
Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity (1982) (173)
Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. (1980) (171)
Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. (1976) (140)
Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. (1981) (134)
Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. (1975) (107)
Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide (1981) (104)
The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. (1978) (103)
Successful immunization with a totally synthetic diphtheria vaccine. (1982) (101)
The macrophage, target cell of the synthetic adjuvant muramyl dipeptide (1978) (93)
A synthetic vaccine constructed by copolymerization of B and T cell determinants (1987) (92)
Immunological castration of male mice by a totally synthetic vaccine administered in saline. (1982) (92)
Muramyl peptides. Variation of somnogenic activity with structure (1984) (91)
Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs (1980) (90)
Mitogenic effect of bacterial peptidoglycans possessing adjuvant activity. (1975) (88)
Central pyrogenic activity of muramyl dipeptide (1980) (86)
Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. (1985) (84)
Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. (1977) (81)
TOLERANCE TO THYROGLOBULIN BY ACTIVATING SUPPRESSOR MECHANISMS * (1982) (79)
Failure of endotoxin to increase nonspecific resistance to infection of lipopolysaccharide low-responder mice (1976) (78)
Isolation of mitogenic and adjuvant active fractions from various species of Nocardiae (1975) (77)
Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. (1979) (77)
Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP). (1978) (76)
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides. (1982) (71)
Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. (1980) (67)
Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. (1987) (65)
Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. (1978) (64)
Future prospects for vaccine adjuvants. (1988) (61)
Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. (1991) (61)
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. (1980) (60)
In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. (1978) (59)
Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine. (1986) (56)
Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative (1982) (54)
Nonspecific activation of murine spleen cells in vitro by a synthetic immunoadjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine). (1977) (53)
Preparation and Biological Properties of Water-Soluble Adjuvant Fractions from Delipidated Cells of Mycobacterium smegmatis and Nocardia opaca (1973) (53)
Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D- isoglutamine, the smallest peptide subunit of bacterial peptidoglycan (1981) (53)
Induction of resistance to Schistosoma mansoni by natural cord factor and synthetic lower homologues. (1980) (52)
Biological study of a nontoxic, water-soluble immunoadjuvant from mycobacterial cell walls. (1972) (49)
Nonspecific immunostimulant activities of synthetic trehalose-6,6'-diesters (lower homologs of cord factor) (1978) (49)
In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP. (1979) (49)
CHARACTERIZATION OF A CR51-LABELED ENDOTOXIN AND ITS IDENTIFICATION IN PLASMA AND URINE AFTER PARENTERAL ADMINISTRATION (1963) (49)
Enhancement of nonspecific immunity to bacterial infection by cord factor (6,6'-trehalose dimycolate). (1977) (47)
A human T-independent B lymphocyte mitogen extracted from Nocardia opaca. (1976) (47)
Blastic transformtion of mouse spleen lymphocytes by a water-soluble mitogen extracted from Nocardia. (1974) (47)
Immunological activities of muramyl peptides. (1986) (47)
Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. (1995) (46)
Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. (1990) (46)
Prevention of endotoxin-induced abortion by treatment of mice with antisera. (1978) (46)
Blast transformation of rabbit B-derived lymphocytes by a mitogen extracted from Nocardia. (1975) (46)
Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide. (1978) (45)
Protective Effect of Chlorpromazine Against Endotoxin-Induced Abortion (1964) (45)
Epitopic suppression in synthetic vaccine models: analysis of the effector mechanisms. (1987) (45)
Muramyl Peptides as Possible Endogenous Immunopharmacological Mediators (1983) (44)
Mitogenic effect of a water-soluble extract of Nocardia opaca: a comparative study with some bacterial adjuvants on spleen and peripheral lymphocytes of four mammalian species. (1974) (43)
Enhancement of resistance to infections by endotoxin-induced serum factor from Mycobacterium bovis BCG-infected mice (1980) (42)
Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. (1979) (41)
Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier (1987) (40)
Selective modulation of lipopolysaccharide-induced death and cytokine production by various muramyl peptides (1995) (40)
Biological activities of endotoxins detoxified by alkylation (1975) (39)
Induction of human interleukin-1 production by polymyxin B. (1987) (39)
Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein. (1984) (38)
Adjuvant requirements for protective immunization of mice using a Trypanosoma cruzi 90K cell surface glycoprotein. (1984) (38)
Inhibition of human IL 2 production by MDP and derivatives. (1984) (37)
Past, present and future of the synthetic immunoadjuvant MDP and its analogs. (1978) (36)
Presence and subcellular localization of two distinct mitogenic fractions in the cells of Nocardia rubra and Nocardia opaca: preparation of soluble mitogenic peptidoglycan fractions (1976) (36)
Epitope specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant. (1983) (35)
Influence of MDP and of some analogous synthetic glycopeptides on the in vitro mouse spleen cell viability and immune response to sheep erythrocytes. (1978) (35)
Selective induction of CD11a,b,c/CD18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides. (1996) (34)
Relationship between chemical structure and adjuvant activity of some synthetic analogues of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP). (1977) (34)
Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem (1986) (33)
Colony-stimulating activity induced by synthetic muramyl peptides: variation with chemical structure and association with anti-infectious activity (1984) (33)
Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat. (1988) (33)
Modulation of myelopoiesis in vivo by synthetic adjuvant-active muramyl peptides: induction of colony-stimulating activity and stimulation of stem cell proliferation (1983) (33)
Strain dependence of muramyl dipeptide-induced LAF(IL 1) release by murine-adherent peritoneal cells. (1985) (33)
Immunological defect and its correction in the osteopetrotic mutant rat. (1977) (31)
In vivo and in vitro stimulation of nonspecific immunity by the beta-D-p-aminophenyl glycoside of N-acetylmuramyl-L-alanyl-D-isoglutamine and an oligomer prepared by cross-linking with glutaraldehyde. (1978) (30)
Increased resistance and depressed delayed-type hypersensitivity to Listeria monocytogenes induced by pretreatment with lipopolysaccharide (1981) (30)
Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens (1984) (30)
Influence of helical organization on immunogenicity and antigenicity of synthetic peptides. (1988) (29)
Protective effects of delipidated mycobacterial cells and purified cell walls against Ehrlich carcinoma and a syngeneic lymphoid leukemia in mice. (1973) (29)
Adjuvants of immunity. (1985) (27)
Influence of a synthetic adjuvant (MDP) on qualitative and quantitative changes of serum globulins. (1978) (27)
Induction of interferon synthesis in mice by fractions from Nocardia (1978) (26)
Effect of muramyl dipeptide on immunogenicity of Corynebacterium pseudotuberculosis whole-cell vaccines in mice and lambs. (1990) (26)
Inhibitory and stimulatory effects of a synthetic glycopeptide (MDP) on the in vitro PFC response: factors affecting the response. (1979) (26)
Selection of a muramyl peptide based on its lack of activation of nuclear factor‐κB as a potential adjuvant for AIDS vaccines (1992) (25)
Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide. (1987) (25)
Marked enhancement of macrophage activation induced by synthetic muramyl dipeptide (MDP) conjugate using monoclonal anti-MDP antibodies. (1984) (24)
Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. (1982) (24)
Studies on visceral Leishmania tropica infection in BALB/c mice. I. Clinical features and cellular changes. (1981) (24)
Amyloidosis and the serum amyloid A protein response to muramyl dipeptide analogs and different mycobacterial species (1983) (24)
Involvement of reactive oxygen metabolites in the candidacidal activity of human neutrophils stimulated by muramyl dipeptide or tumor necrosis factor. (1989) (23)
Induction, in vivo and in vitro, of macrophage membrane interleukin-1 by adjuvant-active synthetic muramyl peptides. (1987) (23)
Synthesis of conjugates containing N-acetylmuramyl-L-alanyl-D-isoglutaminyl (MDP). Their use as hapten-carrier systems. (1980) (22)
Strategies for the treatment of endotoxemia: significance of the acute-phase response. (1987) (22)
Influence of a muramyl dipeptide on human blood leukocyte functions and their membrane antigens. (1991) (22)
Immunological castration by a totally synthetic vaccine: modification of biological properties of LH-RH after conjugation to adjuvant-active muramyl peptide. (1985) (21)
Dissociation of immunostimulant activities of muramyl dipeptide (MDP) by linking amino-acids or peptides to the glutaminyl residue. (1980) (21)
Inheritance of lipopolysaccharide-enhanced nonspecific resistance to infection and of susceptibility to endotoxic shock in lipopolysaccharide low-responder mice (1977) (21)
Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture (1986) (21)
Synergistic effects between recombinant interleukin-2 and the synthetic immunomodulator murabutide: selective enhancement of cytokine release and potentiation of antitumor activity. (1996) (21)
Persistent enhancement of cell-mediated and antibody immune responses after administration of muramyl dipeptide derivatives with antigen in metabolizable oil (1981) (21)
Absence of binding of MDP, a synthetic immunoadjuvant, to anti-peptidoglycan antibodies. (1978) (20)
Fate of two 14C labelled muramyl peptides: Ac-Mur-L-Ala-gamma-D-Glu-meso-A2pm and Ac-Mur-L-Ala-gamma-D-Glu-meso-A2pm-D-Ala-D-Ala in mice. Evaluation of their ability to increase non specific resistance to Klebsiella infection. (1982) (20)
Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs. (1995) (20)
Smooth muscle stimulation by an immunomodulatory compound muramyl dipeptide: does it involve serotoninergic system? (1984) (20)
Cell suppression in PPD-induced blast specific response of human peripheral blood lymphocytes. (1976) (20)
Control of endotoxin activity and interleukin-1 production through regulation of lipopolysaccharide-lipoprotein binding by a macrophage factor (1988) (20)
Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL). (1985) (19)
Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivative (1985) (19)
Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide. (1996) (19)
13 – Muramyl Peptides as Immunopharmacological Response Modifiers (1985) (19)
Effects of natural or synthetic microbial adjuvants on induction of autoimmune thyroiditis (1985) (18)
From the National Institute of Allergy and Infectious Diseases. Summary of an International Symposium on potentiation of the immune response to vaccines. (1980) (18)
Enhancement by muramyl peptides of the protective response of interferon-α/β against encephalomyocarditis virus infection (1996) (18)
Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity. (1990) (18)
Nonspecific enhancement of host defenses against infection: experimental evidence of a new order of efficacy and safety. (1981) (18)
Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria. (1975) (17)
Stimulation of the in vivo dinitrophenyl antibody response to the DNP conjugate of L-glutamic acid60-L-alanine30-L-Tyrosine10 (GAT) polymer by a synthetic adjuvant, muramyl dipeptide (MDP): target cells for adjuvant activity and isotypic pattern of MDP-stimulated response. (1980) (17)
Antibody responses elicited by a polyvalent vaccine containing synthetic diphtheric, streptococcal and hepatitis peptides coupled to the same carrier. (1983) (17)
MDP derivatives and resistance to bacterial infections in mice. (1992) (17)
Macrophage stimulation in vitro by an inactive muramyl dipeptide derivative after conjugation to a multi-poly(DL-alanyl)-poly(L-lysine) carrier (1980) (17)
Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice (1987) (16)
Induction of biologically active antibodies by a polyvalent synthetic vaccine constructed without carrier (1987) (16)
Production of antibodies recognizing a hepatitis B virus (HBV) surface antigen by administration of murabutide associated to a synthetic pre-S HBV peptide conjugated to a toxoid carrier. (1986) (16)
Efficient genetically controlled formation of antibody to a synthetic antigen [poly(LTyr, LGlu)-poly(DLAla)- -poly(LLys)] covalently bound to a synthetic adjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine). (1980) (16)
Enhancement by muramyl dipeptide of in vitro nude mice responses to a T-dependent antigen. (1979) (15)
Specific absorption with monoclonal antibodies to muramyl dipeptide of the pyrogenic and somnogenic activities of rabbit monokine. (1984) (15)
Production of tumor necrosis factor in nude mice by muramyl peptides associated with bacterial vaccines. (1988) (15)
Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A/H3N2 (A/Texas/1/77) virus. (1988) (14)
Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs. (1987) (14)
In vitro effects of lipopolysaccharides and mycobacterial cell wall components on swine alveolar macrophages (1983) (14)
Inhibition of endogenous pyrogen-induced fever by a muramyl dipeptide derivative. (1984) (14)
Induction of colony-stimulating activity (CSA) by a synthetic muramyl peptide (MDP): synergism with LPS and activity in C3H/HeJ mice and in endotoxin-tolerized mice. (1986) (14)
Regulation by muramyl dipeptide (MDP) of the lymphoproliferative responses and polyclonal activation of human peripheral blood mononuclear cells. (1984) (13)
Muramyl dipeptide inhibits replication of human immunodeficiency virus in vitro. (1990) (13)
Attempts to induce resistance to Schistosoma mansoni and S. haematobium in Kenyan baboons (Papio anubis) using non-specific immunostimulants (1985) (13)
Nonspecific resistance to infection induced in mice by a water-soluble adjuvant derived from Mycobacterium smegmatis. (1976) (13)
Synthesis of conjugates between luteinizing hormone releasing hormone (LH-RH) and N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) models of totally synthetic vaccines. (2009) (12)
Role of B-lymphocytes in nonspecific resistance to Klebsiella pneumoniae infection of endotoxin-treated mice. (1976) (12)
Marked enhancement in vivo of adjuvant activity of muramyl dipeptide to protein antigens and to synthetic weak immunogens with monoclonal anti-muramyl dipeptide antibodies (1985) (12)
Lack of general immunosuppression during visceral Leishmania tropica infection in BALB/c mice: augmented antibody response to thymus-independent antigens and polyclonal activation. (1983) (11)
Chemically defined bacterial products with immunopotentiating activity. (1977) (11)
Modulation of murine lymphoma growth by MDP, MDP(D-D) and cyclophosphamide. 1. Inhibition of growth in vivo. (1983) (11)
Influence of CONH2 or COOH as C-terminus groups on the antigenic characters of immunogenic peptides. (1986) (11)
Nonspecific immunoprevention of L1210 leukemia by cord factor (6-6′ dimycolate of trehalose) administered in a metabolizable oil (1976) (11)
In Vitro Attachment of Radioactive Endotoxins to Lysosomes (1971) (11)
Comparison of immunomodulatory activities in mice and guinea pigs of a synthetic desmuramyl peptidolipid triglymyc (1984) (10)
Dissociation between muramyl dipeptide-induced fever and changes in plasma metal levels. (1986) (10)
Effect of muramyl peptides and tumor necrosis factor on oxidative responses of human blood phagocytes. (1989) (10)
Involvement of a radioresistant cell in the production of circulating interferon induced by Nocardia fractions in mice. (1981) (10)
Visceral Leishmania tropica infection of BALB/c mice: cellular analysis of in vitro unresponsiveness to sheep erythrocytes (1982) (10)
Interleukin-1-induced sleep and febrile responses differentially altered by a muramyl dipeptide derivative. (1989) (10)
Inhibition of mitogen-induced polyclonal activation by by a synthetic adjuvant, muramyl dipeptide (MDP). (1980) (9)
Transfer by bone marrow cells of increased natural resistance to Klebsiella pneumoniae induced by lipopolysaccharide in genetically deficient C3H/He mice (1979) (9)
Are there receptors for MDP at the macrophage surface (1986) (9)
Modulation of the growth of murine thymoma cell lines having different Lyt-phenotypes by MDP and MDP(D-D): macrophage-mediated inhibition of in vitro cell growth. (1984) (9)
Production of anti-sporozoite antibodies in absence of response to carrier by coupling an MDP derivative to a malaria peptide-tetanus toxoid conjugate. (1985) (9)
Role of radiosensitive and radioresistant cells in nonspecific resistance to infection of LPS-treated mice. (1977) (9)
In vitro inhibition of murine B-cell tumor growth by MDP, MDP(D-D) and Vaccin is mediated by macrophages. (1985) (9)
Induction of antibodies directed against self and altered-self determinants by a synthetic adjuvant, muramyl dipeptide and some of its derivatives. (1980) (9)
Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: characterization of the specificity. (1983) (9)
Analysis of the antigenic relationship of various derivatives of n-acetyl-muramyl-l-ala-d-isoglutamine (MDP), using anti-MDP antibodies. (1982) (9)
Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents (1984) (8)
Stimulation of human endothelial cells by synthetic muramyl peptides: production of colony-stimulating activity (CSA). (1985) (8)
Changes in Rabbit Febrile Responses to Muramyl Dipeptide (MDP) After Coupling to a Synthetic Carrier (1984) (8)
Role of muramyl peptides for the enhancement of synthetic vaccines. (1986) (8)
Possible role of endotoxemia during immunologic imbalance. (1973) (8)
Enhancement of Human Mixed-Lymphocyte Cultures by a Water-Soluble Adjuvant (1974) (8)
Synthetic muramyl peptides: their origin, present status, and future prospects. Introductory remarks. (1986) (8)
On the Nature of Some Nonspecific Host Responses in Endotoxin-Induced Resistance to Infection (1967) (8)
Stimulation of lymphocytes by purified protein derivative: suppression by cells from human vaccinated with Bacille Calmette-Guérin. (1976) (8)
Enhancement of antibody response to a natural fragment of streptococcal M protein by murabutide administered to healthy volunteers (1985) (7)
Depressed chemiluminescence response by influenza virus is enhanced after conjugation of viral subunits to muramyl dipeptide (1985) (7)
Production of biologically active anti-peptide antibodies in human volunteers immunized with a synthetic peptide of streptococcus pyogenes type 24 M protein (1985) (7)
Induction of colony-stimulating activity in mice by injection of liposomes containing lipophilic muramyl peptide derivatives. (1989) (7)
Influence of indomethacin on various immunopharmacological effects of muramyl dipeptide (MDP). (1980) (7)
Muramyl peptides confer hepatoprotection against murine viral hepatitis (1989) (7)
Enhancement by muramyl peptides of the protective response of interferon-alpha/beta against encephalomyocarditis virus infection. (1996) (7)
Plasminogen activator inhibitor induced by lipopolysaccharide injection in the rat Zymographic analysis (1987) (6)
Epitope specific immunity elicited by totally synthetic monovalent or polyvalent vaccines. (1984) (6)
Nocardia water-soluble mitogen and lipopolysaccharide. Comparative study of two adjuvants and B-cell mitogens in mice. (1977) (6)
Targeting of GM2-bearing tumor cells with the cytolytic Clostridium perfringens delta toxin (1993) (6)
Detection of antibodies to muramyl dipeptide, the adjuvant moiety of streptococcal cell wall, in patients with rheumatic fever. (1986) (6)
Absence of antibodies to muramyl dipeptide in patients with tuberculosis or leprosy. (1982) (6)
Castration of male mice by a synthetic LH-RH-MDP conjugate administered in saline (1982) (6)
Structural requirements for the induction of "immunological castration" by linear monomeric LHRH-lys-MDP administered in saline. (1987) (5)
[Increase of immune response by administration of metabolizable vegetable oil emulsions]. (1975) (5)
Synthetic immunoregulating molecules: A potential bridge between cytostatic chemotherapy and immunotherapy of cancer (1978) (5)
Construction of immunogens for synthetic malaria vaccines. (1988) (5)
Influence of MDP on γ-IFN-induced interleukin 1 production by human monocytes (1985) (5)
Various aspects of synergism between endotoxin and MDPs. (1990) (5)
Influence of hydrocortisone on antibody-dependent lymphoid cell mediated cytotoxicity. (1974) (5)
[Comparative action of promethazine, chlorpromazine and cortisone in mice receiving fatal doses of a bacterial endotoxin]. (1954) (5)
Immunopharmacological Activities of Muramyl Dipeptide, A Synthetic Mycobacterial Analog (1979) (4)
Correction of defective tumoricidal activity of macrophages from A/J mice by liposomal immunomodulators. (1988) (4)
Immunomodulation of macrophages by muramyl peptides: recent findings concerning somnogenic activity of muramyl peptides and monokine. (1984) (4)
In vitro responsiveness of immunocytes to a synthetic immunoadjuvant, muramyl dipeptide, and different synthetic analogs. (1978) (4)
Abrogation of Azidothymidine-Induced Bone Marrow Toxicity by Free and Liposomal Muramyl Dipeptide (1990) (4)
Muramyl Dipeptides, Host Immunity and Enhancement (1987) (4)
Recent advances concerning the use of muramyl dipeptide derivatives as vaccine potentiators. (1980) (4)
Murabutide: An overview of preclinical and clinical activities (1985) (4)
Biological Properties of Non-Toxic Water-Soluble Immunoadjuvants from Mycobacterial Cells (1974) (4)
Immunomodulation by BCG and Synthetic Bacterial-Like Adjuvants (1981) (4)
Modifications of natural killer activity in the mouse by MDP and various muramyl peptides relationship with adjuvant or anti-infectious properties (1985) (4)
Potential use of muramyl peptides in cancer therapy. (1983) (4)
In vivo effects of ovalbumin-conjugated muramyl peptides on the anti-ovalbumin IgE and IgG responses in mice. (1984) (4)
Hybridization by Deoxycholate Treatment or by Biological Degradation of Bacterial Endotoxins Extracted from Smooth and Rough Strains (1970) (4)
Adjuvant disease induced by mycobacteria, determinants of arthritogenicity (1976) (4)
Stimulatory effects of MOP and its butyl ester derivative on macrophage proliferation and activation in vitro (1982) (4)
Changes in absolute number of red blood cells and nucleated cells in the bone marrow caused by endotoxin. (1972) (3)
Experimental Screening of Systemic Adjuvants Extracted from Mycobacteria (1974) (3)
Prevention of low dose streptozotocin induced diabetes by muramyl dipeptide. (1988) (3)
Production and Enhanced Anti‐tumor Activity of Tumor Necrosis Factor in Mice Treated with Cyclophosphamide (1990) (3)
A new non-pyrogenic lipophilic muramylpeptide derivative. I- comparison beteen toxic and antitoxic synergisms with LPS (1991) (3)
Enhancement oftheneonate's nonspecific immunity toKlebsiella infection bymuramyldipeptide, asynthetic immunoadjuvant (analogs ofmycobacterial adjuvants/orally active glycopeptides) (1978) (3)
Effect of cell division inhibitors on polyclonal activation can vary according to the target cell used. (1979) (3)
Production of differentiation-stimulating factor for murine leukemic myeloblast line by monocytic cells stimulated by a nonpyrogenic muramyl dipeptide derivative. (1985) (3)
Influence of endotoxin (51cr) structure on blood clearance in the absence of specific antibodies. (1970) (3)
Selective regulation of lymphokines production by MDP: A key to its immunomodulatory activity? (1985) (3)
A potential anti-pregnancy vaccine built by conjugation of the beta-subunit of human chorionic gonadotropin to adjuvant-active muramyl peptide. (1987) (3)
In Vitro Fixation and Degradation of Radioactive Endotoxin by the RES of BCG-Treated Mice (1971) (3)
Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A and B viruses (1985) (3)
Protective effects of muramyl peptides against experimental viral infections (1985) (3)
MDP stimulation of LAF (IL-1) production by peritoneal macrophages of different strains of mice (1982) (3)
Increased synthesis of fibrinolytic inhibitor induced by muramyl dipeptide derivatives in human cultured endothelial cells. (1985) (3)
Nonspecific Effects of LPS on Bacterial Infections (1986) (3)
In vitro regulation by muramyl dipeptide of interferon production from peripheral blood mononuclear cells of healthy volunteers. (1988) (3)
Stimulation of production of interleukin 1 by polymyxin B (PMB) (1985) (3)
Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents (1984) (3)
Enhanced oxidative burst without interleukin 1 production by normal human polymorphonuclear leukocytes primed with muramyl dipeptides (1987) (2)
Evaluation of natural and synthetic adjuvants in induction of autoimmune thyroiditis (1985) (2)
The Mitogenic Activity of Lipopolysaccharides on Lymphocytes in Culture (1975) (2)
Covalent linkage of the synthetic adjuvant MDP to the synthetic polypeptide (T,G)-A-L changes the specificity of the immune response at the T and B cell level. (1987) (2)
Increased adjuvanticity of MDP by conjugation to mannose: The specific targeting of MDP to macrophages could markedly enhance its activity (1985) (2)
[Sensitization of mice to endotoxins by adrenalectomy or by administration of actinomycin D]. (1971) (2)
Enhancement ofnonspecific immunity toKlebsiella pneumoniae infection byasynthetic immunoadjuvant (N-acetylmuramyl-L- alanyl-D-isoglut amine) andseveral analogs (analogs ofmycobacterial adjuvants/orally active synthetic immunostimulants) (1977) (2)
Activity in saline of phthalylated or succinylated derivatives of mycobacterial water-soluble adjuvant (1976) (2)
[New aspects of the antitoxic action of cortisone]. (1954) (2)
The effect of a water soluble adjuvant on the immune response to synthetic polypeptides. (1978) (2)
Comparison of the effects of an antibacterial leukocytic extract and the serum endotoxin-detoxifying component of lipopolysaccharides extracted from rough and smooth Salmonellae. (1970) (2)
Neuropharmacological activities of MDP. (1986) (2)
The effect of an acute inflammatory process on the resistance to infections in mice (1980) (1)
NWSM, a mitogen from Nocardia opaca, specific for rabbit bursa equivalent cells. (1974) (1)
Role of the proline residues on the immunogenic properties of a P. falciparum circumsporozoite peptide linked to a carrier protein. (1989) (1)
IMMUNOSUPPRESSIVE PROPERTIES OF MURAMYL PEPTIDES (1986) (1)
Antibody response and protective activity with a new synthetic polyvalent vaccine (1985) (1)
[A new family of synthetic immunoregulators: muramyl dipeptide and its analogs]. (1978) (1)
Production of tumor necrosis factor (TNF) in nude mice by administration of muramyl peptides associated to bacterial vaccines (1988) (1)
Fibrinolytic inhibition induced by MDP and LPS in human endothelial cell cultures (1985) (1)
[STUDY OF THE DETOXIFICATION IN VIVO OF A RADIOACTIVE (CR51) ENDOTOXIN. COMPARISON BETWEEN THE ANIMAL TREATED WITH CORTISONE AND THE ANIMAL MADE "TOLERANT"]. (1963) (1)
Evaluation of blood-brain barrier (BBB) permeability during MDP-inducing fever (1985) (1)
International symposium on bacterial immunostimulants: Chemical structure, mechanisms of action, applications (1975) (1)
A new non-pyrogenic muramylpeptide derivative. II- Enhancement of non-specific resistance to infections (1991) (1)
[New aspects of the antitoxic function of cortisone]. (1953) (1)
Book reviewPharmacologie clinique. Bases Thérapeutiques: Edited by J. P. Giroud, G. Mathë and G. Meyniel (2512 pp). 2 Volumes, Expansion Scientifique, Paris, 1978, 1979 (1980) (1)
[Study of the tolerance of adrenalectomized mice using an endotoxin labeled with Cr-51]. (1961) (1)
Effect of MDP (GLu) On Bu on the antibody response against tetanus toxoid in cancer patients (1982) (1)
Secondary anti diphtheria response towards synthetics peptides (1982) (1)
Augmentation de la resistance non specifique a l'infection de la souris apres administration orale de deux glycopeptides synthetiques doues d'activite adjuvante. (1977) (1)
Antibodies to a streptococcal cell wall adjuvant structure persist in patient with chronic rheumatic heart disease. (1989) (1)
Role of Pyrogenic Interleukin-1 in MDP-Induced Hypoferraemia and Hypercupraemia in the Rabbit (1985) (1)
Neuroimmunopharmacological Activities of Muramyl Peptides (1986) (1)
Suppression of in vitro lymphocyte function by cks 17 a synthetic retroviral envelope peptide modulation of suppression by muramyl dipeptide mdp (1989) (1)
Analogifremgangsmaade for the preparation of compounds of muramyldipeptidtypen (1979) (0)
[Demonstration of a bacterial structure in two human mediators: a sleep facilitating factor and a monokine]. (1983) (0)
[Study of a radioactive endotoxin injected into animals during parabiosis]. (1962) (0)
[Deferred physiological action caused by etherification of phenol estrogens]. (1951) (0)
[Anti-inflammatory effect of various bacterial extracts with corticotropic action compared with the corticotropic action of pituitary ACTH]. (1959) (0)
2- (2-acetamido-2-deoxy-3-0-glucopyranosyl) -D-propionyl-L-alanyl-D-glutamic acid (alpha-methyl amide), process for its preparation and containing said compound drug (1977) (0)
[Experimental basis for new treatments for poisoning]. (1954) (0)
[Resistance of the hypophysectomized rat to experimental salmonellosis]. (1960) (0)
[The inhibition of tumors transplanted into mice by the injection of bacterial products]. (1958) (0)
[Not Available]. (1948) (0)
[Increase of non-specific resistance to infection by synthetic adjuvants]. (1979) (0)
[Enhancement of the immune response to influenza vaccine by a synthetic glycopeptide adjuvant (N-acetyl muramy1-L-analyl-D-isoglutamine)]. (1977) (0)
Bidon de gas-oil (1997) (0)
[Action of the placenta in experimental infection of the mouse by Trypanosoma brucei]. (1951) (0)
Decrease in Pyrogenicity of Muramyl Dipeptide After Coupling With Luteinizing Hormone‐Releasing Hormone (1988) (0)
A process for preparing a aktivtinjicertbart stable water-in-oil emulsion composition and means for carrying out the method (1976) (0)
[Anesthetic effect of certain derivatives of allenolic acid]. (1950) (0)
[Effect of bacterial endotoxin in newborn rat]. (1952) (0)
Potentiation by murametide of interferon antiviral activity against encephalomyocarditis infection (1991) (0)
[The immunological activity of a composite antigen obtained by hybridization of endotoxins extracted from rough and smooth strains of "Salmonella" (author's transl)]. (1973) (0)
[The action of cortisone on the sensitivity to bacterial endotoxin in mice]. (1952) (0)
[Enhancement of the activity of hepatitis B virus vaccine by association with murabutide]. (1982) (0)
MURABUTIDE INDUCED PRODUCTION OF NON PYROGENIC INTERLEUKIN 1 BY HUMAN MONOCYTES AND RABBIT MACROPHAGES (1986) (0)
Synthetic molecule containing a plurality distinct epitopes, process for obtaining it and application to the production polyvaccins (1984) (0)
Interferon induced in the hamster by subunits of Nocardia: test of protection against rabies. (1979) (0)
presenting vaccine increased immunogenicity (1994) (0)
New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP (2005) (0)
[Autoimmune aspermatogenetic orchiepididymitis in guinea pigs induced by water-soluble adjuvants]. (1977) (0)
Production of LAF by liver kupffer cells (KC) in response to MDP (1985) (0)
A new non-pyrogenic muramylpeptide derivative. III- anti-myelotoxic activity (1991) (0)
[Thyroid gland and microbial toxins]. (1958) (0)
Lipophilic muramylpeptidderivater and compositions containing them, and processes for producing the derivatives (1985) (0)
Obituary Professor Yuichi Yamamura (1991) (0)
Contents, Vol. 74, 1984 (1984) (0)
immunological adjuvant consisting of p-amino-phenyl N-acetyl-muramyl-L-alanyl-d-isoglutamine (1976) (0)
[Effects of parabiosis on sensitization to histamine of mice immunized with Hemophilus pertussis]. (1955) (0)
[Corticotropins of bacterial origin; specific corticotropic activity of endotoxins]. (1958) (0)
[Study of the abortive action of endotoxins injected into the normal, castrated or hypophysectomized pregnant female mouse]. (1962) (0)
[Corticotrophins of bacterial origin; demonstration of their action in vivo in hypophysectomized rat & in vitro by the Saffran test]. (1958) (0)
[Effects of mycobacterial hydrosoluble adjuvants on the induction and prevention of experimental autoimmune uveo-retinitis in guinea-pigs (author's transl)]. (1979) (0)
Increased Adjuvant Activity of MDP by Direct Coupling of MDP to the Immunogen (1986) (0)
adjuvants and formed of n-acyl-muraminsaeurederivaten vaccines containing (1974) (0)
Compositions based hydrophobic substances dissolvable in an aqueous solvent, process for obtaining them and their uses particularly in the pharmaceutical field. (1990) (0)
[Adrenocortical hyperfunction in pregnancy and overcharging of the liver with glycogens]. (1955) (0)
Studies on in vivo Detoxification of a Radioactive (51Cr) Endotoxin. A Comparison between Cortisone Treated and Tolerant Animals. (1963) (0)
[Influence of serum on certain properties of the methyl ether of dimethylethylallenolic acid]. (1950) (0)
Effect of an antibiotic (bacitracin) on the growth of a young hypophysectomized rat (1960) (0)
Prevention of experimental allergic encephalomyelitis by immunizing guinea pig with an encephalitogenic nonapeptide coupled to tetanus toxoid (1988) (0)
Specific activation of human bone marrow derived lymphocytes by a soluble extract of nocardia opaca (1976) (0)
Enhancement of monokine induction by lipophilic muramyl peptides using monoclonal anti MDP antibodies (1988) (0)
[Study of tolerance to endotoxins in "germ-free" mice by means of a radioactive O antigen]. (1966) (0)
In-vitro activity of an antibacterial substance from rabbit polymorphonuclear leukocytes. (1972) (0)
[Study of the mechanism of the antitoxic action of cortisone by means of parabiosis]. (1953) (0)
[Protective effect of tumor necrosis factor (TNF) obtained by genetic recombination against experimental bacterial or fungal infection]. (1987) (0)
Induction of immunological castration by LHRH administered with a new lipophilic MDP devoid of side effects (1991) (0)
[Use of a water-soluble adjuvant fraction from "Mycobacterium smegmatis" with sperm extract to induce autoimmune aspermatogenic orchiepididymitis in guniea pigs (author's transl)]. (1974) (0)
Construction of Synthetic Immunogens in View of Developing Orally-Active Anti-Enterotoxigenic E. coli Vaccines (1989) (0)
[New contributions relative to the role of "R" antibodies in natural immunity]. (1969) (0)
Fibrinolysis in Endotoxemia (1987) (0)
immunological adjuvants water soluble, including vaccines, obtained from mycobacteria and other microorganisms (1974) (0)
[Anti-pertussis serum inhibition of consecutive sensitization of Hemophilus pertussis vaccination of mice. I. Resistance to histamine. II. Resistance to endotoxins]. (1958) (0)
Current status of the LHRH immunization approach. (1987) (0)
adjuvant agents immunity (1977) (0)
[Disappearance of the anti-endotoxic effect of cortisone in the Hemophilus pertussis-vaccinated mouse]. (1954) (0)
Effect of dexamethasone and endothelial cell supernatant on u-PA produced by human promyelocyte cells treated with phorbol myristate acetate (PMA) (1987) (0)
Modulation of the immunosuppressive activity of CKS-17, a synthetic retroviral envelope peptide, by muramyl dipeptide. (1993) (0)
[Comparison of the effects of estradiol and dimethyl-ethyl-allenolic acid]. (1950) (0)
Induction of plasminogen activator inhibitor (PAI) by lipopolysaccharide (LPS) (1987) (0)
Regulation of IL2 production by muramyl dipeptide and derivatives (1982) (0)
Wasserloesliche adjuvants, methods for their manufacture and to compositions comprising drug (1976) (0)
Bordetella pertussis components given with carrier priming can overcome epitope suppression in synthetic vaccine models (1985) (0)
Serum amyloid a (saa) response to muramyl dipeptide analogs. Abstr. (1982) (0)
fixed muramyl peptides on peptide polymers and drugs containing (1979) (0)
1209 – IMMUNOREGULATING ACTIVITY OF GLYCOPEPTIDES . 2. INFLUENCE OF SOME SUBSTITUTIONS OF THE MURAMYL MOIETY OF MDP (N-ACETYL-MURAMYL-L-ALANYL-D-ISOGLUTAMINE) (1978) (0)
Influence of murametide on human blood leukocyte functions and their membrane antigens (1991) (0)
[The hypophysis and experimental typhoid of the white rat]. (1960) (0)
Disappearance of the Anti-endotoxic Action of Cortisone During Anti-Pertussis Vaccination. (1956) (0)
[Protective effects of bacterial immunostimulants in mice infected by "Klebsiella pneumoniae" resistant to antibiotics after mutation or by plasmid transfer]. (1975) (0)
Diamide 2- (2-acetamido-2-deoxy-3 - od-glucopyranosyl) - d-propionyl-l-alanyl-d-glutamic acid and drugs containing the (1976) (0)
In vivo and in vitro priming effect of muramyl peptides on subsequent cytokine production by LPS (1991) (0)
Role of endogenous pyrogen in the rabbit febrile responses to muramyl dipeptide (Abstract) (1980) (0)
APYROGENIC, ADJUVANT-ACTIVE N-ACETYLMURAMYL-DIPEPTIDES (1982) (0)
Muramylpeptidderivater with lipophilic properties to the activation of macrophages and compositions containing these muramylpeptidderivater (1985) (0)
[Functional relations between dimethylethylallenolic acid and progesterone; new research]. (1953) (0)
[Study of the toxicity of a radioactive endotoxin (Cr 51) injected into normal and hypophysectomized parabionts]. (1963) (0)
Mitogenic agents, process for its production and these drug-containing medium and biological reagents (1975) (0)
[Bacterial endotoxins and homologous disease of the newborn]. (1972) (0)
[Comparative study of antitoxic power of cortisone and chlorpromazine]. (1955) (0)
[Effect of an acute inflammatory process on anti-infectious resistance in mice]. (1979) (0)
Utilization of synthetic MDPs for the induction and prevention of experimental allergic encephalomyelitis (EAE) (1987) (0)
[Role of natural antibodies in the blood clearance of hybridized endotoxins, extracted from smooth and rough strains]. (1972) (0)
[Relation of cortisone to chloramphenical in experimental typhoid in the rat]. (1952) (0)
[Antitumoral effect of peritoneal macrophages activated by a water-soluble adjuvant of mycobacterial origin]. (1974) (0)
[The antibacterial action of certain acids substituted in the alpha position with two methyl groups (allenolic acids and its analogs)]. (1951) (0)
Muramyl Dipeptide Immunoadjuvants (1981) (0)
[Antitoxic action of associated desoxycorticosterone and cortisone]. (1952) (0)
Agents active immunological adjuvants in aqueous solution (1975) (0)
[Adrenals and infection]. (1952) (0)
1210 – IMMUNOREGULATING ACTIVITY OF GLYCOPEPTIDES. I. INFLUENCE OF THE LENGTHENING OF THE PEPTIDE CHAIN OF MDP (N-ACETYL-MURAMYL-L-ALANYL-D-ISOGLUTAMINE) (1978) (0)
[Isolation and characterization of mitogens from Nocardia]. (1977) (0)
[INCREASE IN RESISTANCE TO INFECTIONS FOLLOWING AN INJECTION OF ENDOTOXIN. ROLE OF THE PITUITARY AND ADRENAL]. (1965) (0)
Obituary Federico Spreafico (1940–1994) (1994) (0)
Induction of biologically active antibodies by βhCG conjugated to a synthetic peptide carrier and adminisetred with MDP[THR]GDP in a clinically suitable formulation (1991) (0)
[Interferon induced in the hamster by subunits of "Nocardia": essay of protection against rabies (author's transl)]. (1979) (0)
Ability of a synthetic streptococcal peptide to elicit immunological memory in the absence of detectable antibody production (1985) (0)
[Comparative study of the detoxification of a radioactive endotoxin (51Cr) by citrated serum and spleen extract]. (1969) (0)
1211 – NON-SPECIFIC IMMUNOSTIMULATION BY A p-AMINOPHENYL GLYCOSIDE OF MDP (N-ACETYL-MURAMYL-L-ALANYL-D-ISOGLUTAMINE) AND BY A NEW COMPOUND OBTAINED FROM IT (1978) (0)
Relationships between structure and “anti-pyretic” activity of LH-RH-LYS-MDP (1985) (0)
[Disparities of various effects of cortisone in pregnant rat]. (1954) (0)
(synthetic peptides/vaccine conjugates/protective immunity/rheumatic fever) (2016) (0)
Process for the preparation of compounds of muramylpeptidtypen (1979) (0)
Modulation of interferon-α-induced human monocyte activation by a muramyl dipeptide derivative (1991) (0)
[Increase in the non-specific resistance to infection in mice after oral administration of 2 synthetic glycopeptides with adjuvant activity]. (1977) (0)
[INCREASE IN RESISTANCE TO INFECTIONS FOLLOWING AN ENDOTOXIN INJECTION. DEMONSTRATION OF THE MECHANISM BY SULFONAMIDE ASSOCIATION]. (1965) (0)
[Corticotropins of bacterial origin: specific corticotropic activity of a non-toxic product extracted from a rough strain of Salmonella typhosa]. (1958) (0)
[Effect of cortisone on experimental Salmonella typhi infection in the mouse]. (1951) (0)
Production of High Antibody Levels in Ascitic Fluid obtained by means of Transplantation of Ehrlich Carcinoma into Mice immunized against Haemophilus pertussis. (1959) (0)
[Technic for making hormonal implants by means of a linen thread impregnated with micro-crystals]. (1960) (0)
2003 – IMMUNOPHARMACOLOGICAL ACTIVITIES OF MURAMYL DIPEPTIDE, A SYNTHETIC MYCOBACTERIAL ANALOG (1978) (0)
[Adrenal glands & toxi-infection: why is cortisone a double-edged sword]. (1957) (0)
Workshop 59 – Bacterial Endotoxins (1971) (0)
Use of Muramyl Peptides in Synthetic and Semisynthetic Vaccines (1986) (0)
Compositions for use in human therapy, characterized by the association of a muramyl peptide with a cytokine (1994) (0)
[Adrenocortical hyperfunction in pregnancy and resistance to experimental Salmonella infection]. (1955) (0)
[Action of adrenaline on the effects of a bacterial endotoxin]. (1953) (0)
Immunopharmacologic Approaches to Bacterial Infection (1981) (0)
InVitro Attachment ofRadioactive Endotoxins toLysosomes (1971) (0)
Possibility of a direct pyrogenic effect of muramyl dipeptide (1980) (0)
Immuno stimulatory activity of synthetic poly peptides dissociation of anti infectious activity from adjuvant activity of muramyl di peptide by various procedures (1982) (0)
[Decrease of resistance to histamine in mice maintained at a temperature of 37 degrees C. (98.6 degree F.)]. (1954) (0)
[Increase in resistance to antitoxin by pretreatment with endotoxin injections in the adrenalectomized mouse]. (1955) (0)
[Cortisone in experimental infections in the mouse]. (1953) (0)
Anti-Pertussis Serum inhibits Sensitization following Immunization with H. pertussis in Mice. I.-Resistance to Histamine. II.-Resistance to Endotoxin. (1958) (0)
[Production of an abundant source of antibodies in the ascites fluid obtained by grafting Ehrlich carcinoma to mice vaccinated with Hemophilus pertussis]. (1959) (0)
Lipophilic muramyl peptide derivatives having macrophage activating effect it compositions containing and processes for their preparation. (1985) (0)
Direct and indirect effects of MDP derivatives on thermoregulation (1982) (0)
In vivo activation of murine peritoneal macrophages by Nocardia water soluble mitogen (NWSM). (1979) (0)
[Disappearance of the anti-endotoxic action of cortisone during anti-whooping cough vaccination]. (1956) (0)
God save the swing (1985) (0)
[Effects of ACTH and cortisone on experimental infections and toxi-infectious]. (1956) (0)
[Antitoxic action of chlorpromazine in adrenomedullectomized animals]. (1959) (0)
Priming effect of muramyl peptides for induction of tumor necrosis factor (TNF) production in mice (1988) (0)
and production by various muramyl peptides . cytokinelipopolysaccharide-induced death and Selective modulation of (1994) (0)
[Action of a bacterial extract deprived of antigen O on leukosis of the AkR mouse]. (1960) (0)
[New research on the histamine-sensitizing action of Haemophilus pertussis (phase 1)]. (1960) (0)
[Antihistaminic substances and corpus luteum of the ovary]. (1956) (0)
Emulsion based on a vegetable oil and water stoffwechselfaehigen (1976) (0)
Modulation of the immune response by a synthetic adjuvant and analogs ( analogs of mycobacterial adjuvant / orally active adjuvant / inhibitors of immune response / Gram-negative lipopolysaccharide-low responder mice ) (0)

This paper list is powered by the following services:

Louis A. Chedid's Academic­Influence.com Rankings

Louis A. Chedid's Degrees

Why Is Louis A. Chedid Influential?

Louis A. Chedid's Published Works

Published Works

Louis A. Chedid's AcademicInfluence.com Rankings